TYRA BIOSCIENCES, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 49
- Market Cap
- $1.1B
- Website
- http://www.tyra.bio
- Introduction
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SN?P, enables the rapid and precise refinement of structural design through iterative molecular SN?Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 5,698 Shares
Tyra Biosciences CEO Todd Harris sold 5,698 shares at $24.31 each, totaling $138,518.38, reducing his ownership to 1,496,729 shares worth $36,385,481.99. TYRA stock rose $0.37 to $24.36, with 249,447 shares traded, surpassing average volume. Analysts predict a -1.53 EPS for the current year, with an average rating of 'Moderate Buy' and a consensus target price of $26.40.
President and CEO Harris Todd sold $394,441 worth of shares (16,307 units at $24.19
Tyra Biosciences initiates SURF301 Phase 1/2 study with first patient dosed with TYRA-300, an oral, FGFR3-selective inhibitor for metastatic urothelial carcinoma.
Tyra Biosciences, Inc. (TYRA): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
Oppenheimer's top 32 stock picks for the next 12 months highlight Tyra Biosciences, Inc. (TYRA) as a promising but risky investment due to its clinical-stage status. The firm is optimistic about TYRA's lead drug, TYRA 300, for cancer treatment. Overall, Oppenheimer remains bullish on the stock market, driven by strong economic indicators and potential interest rate cuts.
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for Achondroplasia
Tyra Biosciences received FDA Orphan Drug Designation for TYRA-300, targeting achondroplasia, a common form of dwarfism. TYRA-300, an oral FGFR3 inhibitor, aims to address health complications beyond height. The company plans a Phase 2 study in pediatric achondroplasia by 2024, supported by preclinical success and new leadership in clinical development.
© Copyright 2025. All Rights Reserved by MedPath